Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib

@inproceedings{Cheng2011MolecularMO,
  title={Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib},
  author={Hua Cheng and She-juan An and Song Dong and Yi-fang Zhang and Xuchao Zhang and Zhi-Hong Chen and Jian-Su and Yi-Long Wu},
  booktitle={Journal of hematology & oncology},
  year={2011}
}
BACKGROUND Chemotherapy combined concurrently with TKIs produced a negative interaction and failed to improve survival when compared with chemotherapy or TKIs alone in the treatment of non-small cell lung cancer (NSCLC). The present study investigated the sequence-dependent interaction between paclitaxel and gefitinib and clarified the underlying mechanism. METHODS The effects on cell proliferation, EGFR signaling pathway, and TGFα expression were evaluated in a panel of human NSCLC cell… CONTINUE READING
10 Citations
52 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 52 references

Three-arm randomized Cheng et al

  • EF Smit, JP van Meerbeeck, +7 authors C Manegold
  • Journal of Hematology & Oncology
  • 2011
1 Excerpt

Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406

  • PA Janne, XF Wang, MA Socinski
  • J Clin Oncol
  • 2010
1 Excerpt

Similar Papers

Loading similar papers…